AI Article Synopsis
- [18F]fluoroestradiol (FES) PET is a government-approved imaging method that helps assess how well hormone therapy might work for patients.
- FES positivity indicates that patients are likely to benefit from endocrine therapies, similar to results seen with immunohistochemistry (IHC).
- Recent research showed that measuring tumor heterogeneity with FES can predict treatment success and track changes in estrogen receptor activity during and after treatment.
Article Abstract
[18F]fluoroestradiol (FES) PET is an FDA-approved imaging biomarker. Like IHC, FES positivity predicts clinical benefit of endocrine therapy. In addition, FES measures the target activity in endocrine agent drug development. A recent study found that whole body tumor heterogeneity of expression predicts clinical benefit, and serial FES monitors estrogen receptor blockade and posttreatment release. See related article by Iqbal et al., p. 2075.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1158/1078-0432.CCR-23-0393 | DOI Listing |
Publication Analysis
Top Keywords
predicts clinical
8
clinical benefit
8
molecular imaging
4
imaging find
4
find path
4
path navigate
4
navigate evolving
4
evolving breast
4
breast cancer
4
cancer treatments?
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!